Metformin and cancer: From the old medicine cabinet to pharmacological pitfalls and prospects

Trends in Pharmacological Sciences

Volumn 34, Issue 2, 2013, Pages 126-135

  Emami Riedmaier, Arian ^a   Fisel, Pascale ^a   Nies, Anne T ^a   Schaeffeler, Elke ^a   Schwab, Matthias ^a,b  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; CYCLIN D1; GLUCOSE TRANSPORTER 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; METFORMIN; OCTAMER TRANSCRIPTION FACTOR 1; OCTAMER TRANSCRIPTION FACTOR 4; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE LKB1; PROTEIN P53; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); RETINOBLASTOMA PROTEIN; RHEB PROTEIN; TRANSCRIPTION FACTOR E2F1; TUBERIN; TUMOR NECROSIS FACTOR ALPHA;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BLADDER CANCER; BREAST CANCER; CANCER PREVENTION; COLORECTAL CANCER; DRUG ABSORPTION; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DISPOSITION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG SENSITIZATION; DRUG TARGETING; ENZYME ACTIVATION; GLUCONEOGENESIS; HUMAN; LIVER CANCER; LOW DRUG DOSE; LUNG CANCER; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER;

ANIMALS; ANTICARCINOGENIC AGENTS; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; NEOPLASMS;

EID: 84873412963     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2012.11.005     Document Type: Review

References (100)

1. L.A. Witters The blooming of the French lilac J. Clin. Invest. 108 2001 1105 1107
2. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 352 1998 854 865
3. G.G. Graham Clinical pharmacokinetics of metformin Clin. Pharmacokinet. 50 2011 81 98
4. M.Y. El-Mir Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I J. Biol. Chem. 275 2000 223 228
5. X. Stephenne Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status Diabetologia 54 2011 3101 3110
6. J.E. Gunton Metformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin-receptor substrate-2 J. Clin. Endocrinol. Metab. 88 2003 1323 1332
7. J. Wang Metformin activates an atypical PKC-CBP pathway to promote neurogenesis and enhance spatial memory formation Cell Stem Cell 11 2012 23 35
8. M. Pollak Metformin and other biguanides in oncology: advancing the research agenda Cancer Prev. Res. 3 2010 1060 1065
9. E. Giovannucci Diabetes and cancer: a consensus report Diabetes Care 33 2010 1674 1685
10. M. Pollak Insulin and insulin-like growth factor signalling in neoplasia Nat. Rev. Cancer 8 2008 915 928
11. G. Libby New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes Diabetes Care 32 2009 1620 1625
12. C.J. Currie The influence of glucose-lowering therapies on cancer risk in type 2 diabetes Diabetologia 52 2009 1766 1777
13. T. Patel Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin Urology 76 2010 1240 1244
14. S. Jiralerspong Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer J. Clin. Oncol. 27 2009 3297 3302
15. P.J. Goodwin Insulin-lowering effects of metformin in women with early breast cancer Clin. Breast Cancer 8 2008 501 505
16. S. Hadad Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial Breast Cancer Res. Treat. 128 2011 783 794
17. B. Bonanni Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial J. Clin. Oncol. 30 2012 2593 2600
18. K. Hosono Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial Cancer Prev. Res. 3 2010 1077 1083
19. M.C. Towler, and D.G. Hardie AMP-activated protein kinase in metabolic control and insulin signaling Circ. Res. 100 2007 328 341
20. R.J. Shaw The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin Science 310 2005 1642 1646
21. D.M. Gwinn AMPK phosphorylation of raptor mediates a metabolic checkpoint Mol. Cell 30 2008 214 226
22. K. Inoki TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling Nat. Cell Biol. 4 2002 648 657
23. K.E. Bachman The PIK3CA gene is mutated with high frequency in human breast cancers Cancer Biol. Ther. 3 2004 772 775
24. J. Liang The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis Nat. Cell Biol. 9 2007 218 224
25. L. Galluzzi TP53 and MTOR crosstalk to regulate cellular senescence Aging (Albany N.Y.) 2 2010 535 537
26. M. Foretz Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state J. Clin. Invest. 120 2010 2355 2369
27. A. Kalender Metformin, independent of AMPK, inhibits mTORC1 in a Rag GTPase-dependent manner Cell Metab. 11 2010 390 401
28. M. Arai Metformin, an antidiabetic agent, suppresses the production of tumor necrosis factor and tissue factor by inhibiting early growth response factor-1 expression in human monocytes in vitro J. Pharmacol. Exp. Ther. 334 2010 206 213
29. R. Hill, and H. Wu PTEN, stem cells, and cancer stem cells J. Biol. Chem. 284 2009 11755 11759
30. I. Ben Sahra The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level Oncogene 27 2008 3576 3586
31. C. Algire Metformin reduces endogenous reactive oxygen species and associated DNA damage Cancer Prev. Res. 5 2012 536 543
32. K. Zhou Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes Nat. Genet. 43 2011 117 120
33. A. Vazquez-Martin Metformin activates an ataxia telangiectasia mutated (ATM)/Chk2-regulated DNA damage-like response Cell Cycle 10 2011 1499 1501
34. J.A. Menendez Metformin and the ATM DNA damage response (DDR): accelerating the onset of stress-induced senescence to boost protection against cancer Aging (Albany N.Y.) 3 2011 1063 1077
35. L. Dong Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression J. Obstet. Gynaecol. Res. 2012 10.1111/j.1447-0756.2011.01839.x
36. H.A. Hirsch Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission Cancer Res. 69 2009 7507 7511
37. C.W. Song Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells Sci. Rep. 2 2012 362
38. C. Algire Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo Oncogene 30 2011 1174 1182
39. E. Schaeffeler DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma Genome Med. 3 2011 82
40. K. Damme Mammalian MATE (SLC47A) transport proteins: impact on efflux of endogenous substrates and xenobiotics Drug Metab. Rev. 43 2011 499 523
41. A.T. Nies Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver Hepatology 50 2009 1227 1240
42. Y. Shu Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action J. Clin. Invest. 117 2007 1422 1431
43. A.T. Nies Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy Handb. Exp. Pharmacol. 201 2011 105 167
44. M.V. Tzvetkov The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin Clin. Pharmacol. Ther. 86 2009 299 306
45. M.L. Becker Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus Pharmacogenomics J. 9 2009 242 247
46. A. Gambineri Organic cation transporter 1 polymorphisms predict the metabolic response to metformin in women with the polycystic ovary syndrome J. Clin. Endocrinol. Metab. 95 2010 E204 E208
47. N. Kimura Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1 Drug Metab. Pharmacokinet. 20 2005 379 386
48. M.K. Leabman, and K.M. Giacomini Estimating the contribution of genes and environment to variation in renal drug clearance Pharmacogenetics 13 2003 581 584
49. I-S. Song Pharmacogenetics meets metabolomics: discovery of tryptophan as a new endogenous OCT2 substrate related to metformin disposition PLoS ONE 7 2012 e36637
50. L. Chen Genetic and epigenetic regulation of the organic cation transporter 3, SLC22A3 Pharmacogenomics J. 2012 10.1038/tpj.2011.60
51. L. Chen Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin Pharmacogenet. Genomics 20 2010 687 699
52. Y. Chen Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function Pharmacogenomics J. 9 2009 127 136
53. J.H. Choi A common 5′-UTR variant in MATE2-K is associated with poor response to metformin Clin. Pharmacol. Ther. 90 2011 674 684
54. K. Toyama Loss of multidrug and toxin extrusion 1 (MATE1) is associated with metformin-induced lactic acidosis Br. J. Pharmacol. 166 2012 1183 1191
55. T. Komatsu Characterization of the human MATE2 proton-coupled polyspecific organic cation exporter Int. J. Biochem. Cell Biol. 43 2011 913 918
56. M. Kajiwara Identification of multidrug and toxin extrusion (MATE1 and MATE2-K) variants with complete loss of transport activity J. Hum. Genet. 54 2009 40 46
57. M.L. Becker Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study Diabetes 58 2009 745 749
58. J. Ha Choi Identification and characterization of novel polymorphisms in the basal promoter of the human transporter, MATE1 Pharmacogenet. Genomics 19 2009 770 780
59. H.E. Meyer zu Schwabedissen Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms Am. J. Physiol. Renal Physiol. 298 2010 F997 F1005
60. M. Zhou Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine Drug Metab. Dispos. 35 2007 1956 1962
61. L. Xia Membrane localization and pH-dependent transport of a newly cloned organic cation transporter (PMAT) in kidney cells Am. J. Physiol. Renal Physiol. 292 2007 F682 F690
62. + symporters (MCTs): metformin sensitizes MCT inhibition Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research 2012 American Association for Cancer Research 72
63. C. Pinheiro Role of monocarboxylate transporters in human cancers: state of the art J. Bioenerg. Biomembr. 44 2012 127 139
64. K.A. Jablonski Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program Diabetes 59 2010 2672 2681
65. R.S. Legro Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene J. Clin. Endocrinol. Metab. 93 2008 792 800
66. M.R. Ballestero Expression of transporters potentially involved in the targeting of cytostatic bile acid derivatives to colon cancer and polyps Biochem. Pharmacol. 72 2006 729 738
67. N. Kitada Factors affecting sensitivity to antitumor platinum derivatives of human colorectal tumor cell lines Cancer Chemother. Pharmacol. 62 2008 577 584
68. M. Aoki Kidney-specific expression of human organic cation transporter 2 (OCT2/SLC22A2) is regulated by DNA methylation Am. J. Physiol. Renal Physiol. 295 2008 F165 F170
69. T. Minematsu, and K.M. Giacomini Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins Mol. Cancer Ther. 10 2011 531 539
70. R. Kerb, and M. Schwab Impact of pharmacogenetics on drug-drug interactions Enzyme- and Transporter-Based Drug-Drug Interactions: Progress and Future Challenges 2010 Springer pp. 51-74
71. A.T. Nies Multidrug and toxin extrusion (MATE) proteins as transporters of antimicrobial drugs Expert Opin. Drug Metab. Toxicol. 8 2012 1565 1577
72. A.T. Nies Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs) PLoS ONE 6 2011 e22163
73. S.W. Yee The role of ATM in response to metformin treatment and activation of AMPK Nat. Genet. 44 2012 359 360
74. J. Pan Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells Cell Cycle 11 2012 2314 2326
75. W-Y. Shi Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy Cell Death Dis. 3 2012 e275
76. M.N. Pollak Investigating metformin for cancer prevention and treatment: the end of the beginning Cancer Discov. 2 2012 778 790
77. U.A. Meyer Omics and drug response Annu. Rev. Pharmacol. Toxicol. 2012 10.1146/annurev-pharmtox-010510-100502
78. E.D. Segal Relevance of the OCT1 transporter to the antineoplastic effect of biguanides Biochem. Biophys. Res. Commun. 414 2011 694 699
79. A. Decensi Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis Cancer Prev. Res. 3 2010 1451 1461
80. J. Johnson, and S.L. Bowker Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials Diabetologia 54 2011 25 31
81. N.F. Col Metformin and breast cancer risk: a meta-analysis and critical literature review Breast Cancer Res. Treat. 2012 10.1007/s10549-012-2170-x
82. H. Noto Cancer Risk in diabetic patients treated with metformin: a systematic review and meta-analysis PLoS ONE 7 2012 e33411
83. D. Soranna Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis Oncologist 17 2012 813 822
84. Z-J. Zhang Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis Diabetes Care 34 2011 2323 2328
85. Z-J. Zhang Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis J. Clin. Endocrinol. Metab. 97 2012 1 7
86. R.T. Chlebowski Diabetes, metformin, and breast cancer in postmenopausal women J. Clin. Oncol. 30 2012 2844 2852
87. J.P. Nobes A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy BJU Int. 109 2012 1495 1502
88. I.S. Song Genetic variants of organic cation transporter 2 (OCT2) significantly reduce metformin uptake in oocytes Xenobiotica 38 2008 1252 1262
89. M.K. Leabman Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function Pharmacogenetics 12 2002 395 405
90. K. Toyama Heterozygous variants of multidrug and toxin extrusions (MATE1 and MATE2-K) have little influence on the disposition of metformin in diabetic patients Pharmacogenet. Genomics 20 2010 135 138
91. M.J. Cutler, and E.F. Choo Overview of SLC22A and SLCO families of drug uptake transporters in the context of cancer treatments Curr. Drug Metab. 12 2011 793 807
92. M. Heise Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance BMC Cancer 12 2012 109 119
93. N. Merezhinskaya, and W.N. Fishbein Monocarboxylate transporters: past, present, and future Histol. Histopathol. 24 2009 243 264
94. K. Engel Identification and characterization of a novel monoamine transporter in the human brain J. Biol. Chem. 279 2004 50042 50049
95. H. Duan, and J. Wang Selective transport of monoamine neurotransmitters by human plasma membrane monoamine transporter and organic cation transporter 3 J. Pharmacol. Exp. Ther. 335 2010 743 753
96. Y. Shu Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1 Proc. Natl. Acad. Sci. U.S.A. 100 2003 5902 5907
97. R. Kerb Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences Pharmacogenetics 12 2002 591 595
98. Y. Shu Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics Clin. Pharmacol. Ther. 83 2008 273 280
99. H-J. Kang Identification and functional characterization of genetic variants of human organic cation transporters in a Korean population Drug Metab. Dispos. 35 2007 667 675
100. E. Shikata Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin J. Hum. Genet. 52 2007 117 122